无功能垂体腺瘤术后进展相关的蛋白质组学特征
这项在三级大学医院开展的病例对照探索性研究,对46例性腺滋养细胞谱系无功能垂体腺瘤术后残留肿瘤患者进行组织蛋白质组学分析,比较需再次干预的进展组(29例)与至少5年影像学稳定组(17例)。全局定量蛋白质组学共鉴定4074种蛋白,其中550种差异表达;再干预组中SNRPD1、SRSF10、SWAP-70和PSMB1等蛋白上调,这些蛋白在其他癌种中与肿瘤进展相关。作者认为蛋白质组学分析对预测无功能垂体腺瘤术后进展可能有价值。
要点
- 共鉴定4074种蛋白,其中550种在进展组与稳定组间差异表达。
- 主成分分析显示两组分离良好。
- 再干预组中SNRPD1、SRSF10、SWAP-70和PSMB1等蛋白上调,与其他癌种的肿瘤进展相关。
核心结论
- 这是首个分析蛋白质组学特征作为无功能垂体腺瘤术后肿瘤进展标志物的探索性研究。
- 研究结果显示,术后行为惰性的肿瘤与术后肿瘤进展的肿瘤具有不同的蛋白质组学特征。
- 差异表达蛋白所富集的通路及特定上调蛋白此前均与肿瘤侵袭性相关。
- 这些结果提示蛋白质组学分析对预测无功能垂体腺瘤患者肿瘤进展可能有价值。
研究设计与样本
- 本研究为三级大学医院的病例对照探索性研究。
- 组织样本来自46例性腺滋养细胞谱系无功能垂体腺瘤术后残留肿瘤患者。
- 比较两组:因残留肿瘤进展需再次干预的患者(病例组,再干预组,n=29)与残留肿瘤至少5年无进展的患者(对照组,影像学稳定组,n=17)。
- 检测两组间的差异表达蛋白。
主要发现
- 全局定量蛋白质组学分析鉴定出4074种蛋白,其中550种在两组间差异表达(倍数变化>80%,错误发现率校正P≤.05)。
- 主成分分析显示两组分离良好。
- 差异表达蛋白的功能富集分析提示涉及翻译、ROBO受体信号、能量代谢、mRNA代谢和RNA剪接等过程。
- 再干预组中SNRPD1、SRSF10、SWAP-70和PSMB1等蛋白上调,这些蛋白与其他癌种的肿瘤进展相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: There is a lack of reliable biomarkers capable of predicting postoperative tumor progression of nonfunctioning pituitary adenomas (NFPAs). OBJECTIVE: To discover proteomic profiles associated with postoperative tumor progression in patients with NFPAs. This was a case-controlled exploratory study at a tertiary university hospital. Tissue samples were obtained from 46 patients with residual tumor following surgery for NFPAs of gonadotroph lineage. Two patient groups were compared: patients requiring reintervention due to residual tumor progression (cases; reintervention group, n = 29) and patients with a residual tumor showing no progression for a minimum of 5 years (controls; radiologically stable group, n = 17). Differentially expressed proteins (DEPs) between patient groups were measured. RESULTS: Global quantitative proteomic analysis identified 4074 proteins, of which 550 were differentially expressed between the 2 groups (fold change >80%, false discovery rate-adjusted P ≤ .05). Principal component analysis showed good separation between the 2 groups. Functional enrichment analysis of the DEPs indicated processes involving translation, ROBO-receptor signaling, energy metabolism, mRNA metabolism, and RNA splicing. Several upregulated proteins in the reintervention group, including SNRPD1, SRSF10, SWAP-70, and PSMB1, are associated with tumor progression in other cancer types. CONCLUSION: This is the first exploratory study analyzing proteomic profiles as markers of postoperative tumor progression in NFPAs. The findings clearly showed different profiles between tumors with indolent postoperative behavior and those with postoperative tumor progression. Both enriched pathways involving DEPs and specific upregulated proteins have previously been associated with tumor aggressiveness. These results suggest the value of proteomic profiling for predicting tumor progression in patients with NFPAs.
引用
- Hallén T, Johannsson G, Thorsell A, et al. Proteomic Profiles Associated With Postsurgical Progression in Nonfunctioning Pituitary Adenomas. J Clin Endocrinol Metab. 2024. PMID: 38157275. doi:10.1210/clinem/dgad767
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。